Cabozantinib: payments to doctors
Payments that named Cabozantinib as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.7M
- Providers
- 28
- Transactions
- 159
- Average per transaction
- $10,799
The per-transaction average — $10,799 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 28 providers the average total is $61,321, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Exelixis Inc. | $1,716,998 | 100.0% |